Video

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

Author(s):

Ritu Salani, MD,Ursula A. Matulonis, MD

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Related Videos
Chad Tang, MD
Domenica Lorusso, MD, PhD
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Domenica Lorusso, MD, PhD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Marc Machaalani, MD
Related Content
David C. Fisher, MD, of Dana-Farber Cancer Institute
October 21st 2024

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Christine Auberle, MD, cochief fellow, hematology and oncology, Washington University School of Medicine in St. Louis
October 21st 2024

Optimizing Training for Future Clinical Trial Investigators

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Susana Banerjee, MBBS, MA, PhD, FRCP, consultant medical oncologist, The Royal Marsden NHS Foundation Trust; team leader, Women’s Cancers, The Institute of Cancer Research
October 17th 2024

Updated RAMP 201 Data to Support NDA Submission for Avutometinib/Defactinib Combo in Recurrent KRAS+ Ovarian Cancer

Nancy Lin, MD
October 16th 2024

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases